Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.39 |
| ▸ | CNR2 | P34972 | 9/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170199 | 0.81 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1CNR2 | |
| SCHEMBL13501749 | 0.81 | CNR2 (0.39) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13435110 | 0.79 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13499740 | 0.78 | SLC1A3 (0.36) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13461495 | 0.78 | SLC1A3 (0.36) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13501743 | 0.75 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1CNR2CNR1 | |
| SCHEMBL13499748 | 0.73 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13435118 | 0.73 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1CNR2 | |
| SCHEMBL13461544 | 0.72 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL30170112 | 0.72 | SMN1; SMN2 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SLC1A3 3674/4885SLC1A2 4427/4885SLC1A1 3852/4885 |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SLC1A3 3674/4885SLC1A2 4427/4885SLC1A1 3852/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | SLC1A3 3674/4885SLC1A2 4427/4885SLC1A1 3852/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SLC1A3 3674/4885SLC1A2 4427/4885SLC1A1 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.